Check out your Company Bowl for anonymous work chats.
Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months The life science group Sartorius continued its profitable growth course and considerably increased both sales revenue and profitability in the first nine months of fiscal 2025. Sartorius CEO Dr. Michael Grosse said: “We are very positive about our progress this year so far. With double-digit growth, our high-margin consumables business remains our key growth driver. Even though customers are still cautious about investing in equipment and instruments, this business is stabilizing. It is equally encouraging to see that the lab division is proving resilient in a persistently challenging market environment and keeps catching up. Against this backdrop, we are sharpening the full-year forecast and expect Group sales revenue to reach the upper half of the previously defined range.” - Group sales revenue up 7.5% in the first nine months - Significant growth in recurring business with consumables continues - Double-digit increase of underlying EBITDA - Underlying EBITDA margin up 2 percentage points - Guidance for 2025 sharpened Read the full media release: https://sar.to/wpksi
Sartorius continues its profitable growth path in the first half of 2025, achieving significant increases in sales revenue and profitability. 💬”We are satisfied with the business results for the first half of the year; the upward trend is continuing. We saw the expected growth momentum in the particularly high-margin business with consumables for pharma, which is of greatest relevance to us. I think we are well on track to achieve our ambitious targets for the year despite the difficult global environment,” said Sartorius’ new CEO Dr. Michael Grosse, who took over the position on July 1, 2025. ➡️ Sales revenue up 6.1 percent in constant currencies, with all regions contributing ➡️ Underlying EBITDA margin reaches 29.8 percent ➡️ Business with consumables continues to grow in both divisions ➡️ Guidance for 2025 confirmed
Strong start to the year: Sartorius achieves significant profitable growth in Q1 💬 "The fundamental growth drivers of our industry are increasingly playing the central role again. Demand for biologics – often the only effective therapies for severe diseases – will continue to rise sustainably, along with the strong need for innovative technologies that make their development and manufacture faster and more efficient. This is precisely our strategic and operational focus," said Sartorius CEO Joachim Kreuzburg. ➡️ Sales revenue up 6.5 percent ➡️ High demand for consumables ➡️ Very good order intake development ➡️ Guidance: robust sales growth & profitability 🔗 Read media release: https://sar.to/sqvkl
Attention life science communicators, this is your call for entries! The LifeScienceXplained | Sartorius Award for New Communication is back. Can you make complex life science topics crystal clear for a broad audience with creative formats such as videos, podcasts, illustrations or science slams? Show us your best work and win 15,000 euros in prize money! Enter as a team or as an individual. If you have a channel, pick your favorite content pieces - multiple submissions are welcome. The date of first publication must be between August 1, 2024 and August 1, 2025. Our independent jury will select three finalists - and the winner! The award ceremony will take place on November 6 as part of the Göttinger Literaturherbst festival at the Sartorius Campus in Göttingen. Take your chance and apply by August 7, 2025 at www.sartorius.com/lsx!
International Women's Day 2025 – Let's accelerate action! International Women's Day (IWD) is around the corner, where we celebrate the achievements of women around the world while emphasizing the need to #AccelerateAction on the ongoing journey towards gender equality. This year's IWD theme "Accelerate Action" strongly aligns with our commitment at Sartorius to promote gender parity and diversity, because we believe that bringing together diverse perspectives is key to our mission of simplifying progress in life sciences and bioprocessing. Our employees are at the heart of this journey. Their everyday actions positively impact women's advancements and create an environment, where everyone can thrive and contribute to shared success. Learn more on the Sartorius Blog: www.sartorius.com/blog
“A successful start! Membrane filters have become indispensable in the examination of viruses, bacteria, and bacteriophages. We owe this to Dr. Beling”. – Gertrud Keese, Operations Manager and Procurator of Sartorius Membrane Filter Company, 1952 In celebration of the upcoming International Women's Day, we spotlight Dr. Adelaide Beling. Her pioneering work in the 1950s laid the economic foundation for the filter business by introducing dry filters and the so-called membrane filter method, which streamlined bacteriological water quality testing. This innovation was crucial in post-war Germany, where rapid and effective water testing was essential to prevent diseases. Adelaide Beling's example beautifully illustrates the historical roots of Sartorius' mission, while highlighting the vital, yet often overlooked, role women have played early on in advancing science and technology. Learn more on the Sartorius Blog: https://sar.to/ozc6j
Women Careers at Sartorius With International Women’s Day coming up on March 8, we spotlight the 5,245 women at Sartorius, who are working towards our ambition of enabling better health for more people while, advancing their careers, and growing with the company. Did you know that 44% of internal management hires at Sartorius in 2024 were female? Check out more facts and figures on the Sartorius blog: https://sar.to/flm4p
The life science group Sartorius released its Annual Report for 2024 today. CEO Joachim Kreuzburg: "Looking ahead, we are confident, as the fundamental growth drivers of the life science and biopharmaceutical industries remain very positive. Sartorius has one of the most comprehensive product portfolios on the market: from AI-supported bioanalytical tools for the development of pharmaceuticals to innovative technologies for the entire range of manufacturing processes for biologics and critical reagents for cell and gene therapies. With this product portfolio, the company is excellently positioned for further growth and also significantly contributes to making new therapies more affordable and available to patients." Read more: https://sar.to/m0j4y
Meet Sartorius’ services teams 🚗🔧 Ever wondered who ensures that essential tools and technologies for developing and manufacturing medications for cancer, inheritable diseases, and future pandemics work seamlessly? This is where the Sartorius services teams come in. They play a crucial role in supporting researchers and manufacturers in the life sciences and biopharma industry, who work on translating scientific discoveries into real-world medicine. 🌍🔬 💉 On the Sartorius blog, learn about the day-to-day work of our services experts, from supporting customers on-site, to building lasting relationships - all while advancing their own careers: https://sar.to/4uw5q
Sartorius closes fiscal 2024 with very good fourth quarter and positive trend According to preliminary figures, the company maintained its strong market position and high profitability in 2024, and generated sales revenue at the previous year’s level despite the difficult industry environment that lasted longer than expected. Sartorius fully met its growth and profitability targets, as adjusted at mid-year. For 2025, management expects profitable, moderate growth above market level. “Business development in the second half of the year, and especially in the final quarter, confirms our estimate that the temporary weakness in demand is coming to an end, and that the industry will gradually return to its robust, structurally underlying growth trend,” said Sartorius CEO Joachim Kreuzburg. - Sales revenue at previous year's level - Growth & profitability targets fully met - Very good Q4 and positive trend Read media release: https://sar.to/knxbm
